C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy.
Narendranath EpperlaKami J MaddocksMohammed SalhabJulio C ChavezNishitha ReddyReem KarmaliElvira UmyarovaVeronika BachanovaCristiana CostaMartha GlennOscar CalzadaAna C XavierZheng ZhouNasheed M HossainFrancisco J Hernandez-IlizaliturriZeina Al-MansourStefan K BartaSaurabh ChhabraFrederick LansiganAmitkumar MehtaMichael V JaglalAndrew M EvensChristopher R FlowersJonathon B CohenTimothy S FenskeMehdi HamadaniLuciano J CostaPublished in: Cancer (2017)
Patients with MYC-positive DLBCL who experience primary treatment failure have response rates to similar to those achieved by salvage therapy compared with their MYC-negative counterparts, but their survival is dismal irrespective of additional "hits" and HCT, representing an unmet medical need. Cancer 2017;123:4411-8. © 2017 American Cancer Society.
Keyphrases
- diffuse large b cell lymphoma
- papillary thyroid
- epstein barr virus
- squamous cell
- healthcare
- acute lymphoblastic leukemia
- acute myeloid leukemia
- lymph node metastasis
- type diabetes
- stem cells
- adipose tissue
- squamous cell carcinoma
- cell proliferation
- mesenchymal stem cells
- insulin resistance
- cell therapy
- hodgkin lymphoma
- weight loss
- glycemic control
- combination therapy